Last reviewed · How we verify

Gymnema Sylvestre

University of Guadalajara · FDA-approved active Small molecule Quality 15/100

Gymnema Sylvestre, marketed by the University of Guadalajara, is positioned in the pancreatic support segment. The key composition patent, set to expire in 2028, provides a significant competitive advantage. The primary risk is the lack of reported revenue and key trial results, which may impact market confidence and adoption.

At a glance

Generic nameGymnema Sylvestre
Also known asGurmar
SponsorUniversity of Guadalajara
Drug classStandardized Chemical Allergen [EPC]
ModalitySmall molecule
PhaseFDA-approved

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: